An interventional study of Saline Nebulization and Heated humidification in Excessive Airway Secretions, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment
This study aims to evaluate whether adding a continuous mist of saltwater (saline nebulization) to warmed, humidified air can improve the properties of mucus in the lungs compared to humidified air alone.
Some patients with chronic lung diseases produce large amounts of thick mucus, which can be difficult to clear and may worsen breathing. Making this mucus easier to move and remove could help improve comfort and breathing.
In this study, 35 adult patients hospitalized for lung conditions with excessive mucus production will participate. Each patient will receive both treatments on two different days, in a random order:
Heated humidified air alone Heated humidified air combined with continuous saline nebulization This design allows each patient to serve as their own comparison. At the beginning and end of each session, a physiotherapist will help patients clear their airways, and mucus samples will be collected. Each treatment session will last 4 hours.
The collected mucus will be analyzed in a laboratory to measure how thick, sticky, or elastic it is, and how much force is needed to move it. The main goal is to determine whether the combined treatment makes mucus easier to clear.
The study will also assess patient comfort, breathing difficulty, ease of clearing mucus, and sleep quality after treatment.
The results of this study may help improve airway care for patients with chronic lung diseases by identifying more effective ways to manage excessive mucus.
Aim- The objective of this study is to determine the effect of continuous isotonic saline nebulization combined with heated humidification on mucus rheology characteristics compared with heated humidification alone.
Design study- This experimental study will follow a cross-over design. As mucus rheology characteristics vary among individuals, this design will enable each subject to be his own control.
Population- 35 patients with excessive airway secretions will be included in this study (sample size calculated with a 95% confidence level and 80% power). Patients will undergo screening for eligibility upon admission to the pulmonology unit. Individuals with chronic pulmonary conditions leading to excessive airway secretions (> 20 mL of expectoration per day) and meeting the inclusion criteria will be invited to participate in the study. The study will take place on two days, after inclusion, randomization will determine the sequence of administration for the two treatments being compared.
Intervention- A continuous isotonic saline nebulization will be delivered combined with a heated humidification.
The continuous nebulization will be performed using the Aerogen continuous nebulization set to assure the continuous supply of isotonic saline solution into the aerogen solo mesh nebulizer.
The heated humidification will be delivered by Airvo 3 (Fisher \& Paykel, Auckland, New Zeeland). Air flow will be set at 25L/min, temperature at 37°C and FiO2 will be set to obtain the SpO2 targeted by the physician.
The nebulizer will be installed on the airvo, thus saline particles will be delivered through the nasal prong.
Control- The heated humidification will be delivered by Airvo 3 (Fisher \& Paykel, Auckland, New Zeeland). Air flow will be set at 25L/min, temperature at 37°C and FiO2 21%.
Experimental setting- The study will take place on two days. Subject will experience the intervention and the control treatment on a randomized order.
At the beginning of each experimental session manuals airway clearance maneuvers will be performed by a trained physiotherapist and mucus expectorated will be sampled. After secretion samples subject will undergo treatment, according to the randomization treatment order, for a 4-hour period. A new airway clearance session will be performed at the end pf the 4-hour period with secretion sampling. No Positive Expiratory Pressure or Oscillatory Positive Expiratory Pressure devices will be used to prevent from viscosity modification
Rheological measurements- Rheological measurement will be conducted using the rheometer MCR102 (Anton-Paar,Graz, Austria). Prior to analysis, the sputum will be incubated at 37°C for 30 min before analysis to allow relaxation of the sample. The rheometer comprises two parallels plates which will gently compress the secretion. The lower plate will perform oscillations with controlled angular displacement while the rheometer will measure the torque exerted on the opposite plate during these oscillations. Data will be captured using RheoCompassTM software (Anton-Paar) and various data will be extracted from this analysis.
During the linear phase of the analysis, the investigator will register the elastic modulus (G'), the viscous modulus (G''), the viscoelastic modulus (G*), the damping coefficient (tan δ ratio of G'' and G'). These data will provide insights into the secretion's propensity toward elasticity (solid-like) or viscosity (liquid-like).
During the non-linear phase of the analysis, the investigator will register the critical strain (γc) which represent the secretion's deformability capacity, the critical stress (τc) indicating the force required to initiate sputum flow, and the elastic force (G*p x τc) reflecting the elastic energy of the secretion that must be overcome to induce flow. These data will provide insights into the force required for patient airway clearance.
Outcomes- The primary outcomes will be the difference of the force required to evacuate the secretions between the two treatments (τc).
The secondary outcomes will include:
Exclusion Criteria:
Device: Saline Nebulization · Device: Heated humidification
Device: Heated humidification
Continuous saline nebulization through HFNC
Heated humidification through HFNC
Critical strain
Rheological property
Time frame: On each experimental session (4hours) the outcome will be measured at the onset on the experiment, which mean prior to the application of the treatment / control and at the end of the experiment which mean 4 hours after the onset.
Elastic and viscous modulus
Time frame: On each experimental session (4hours) the outcome will be measured at the onset on the experiment, which mean prior to the application of the treatment / control and at the end of the experiment which mean 4 hours after the onset.
Comfort
Lickert scale 0 - 6, higher score is a better outcome
Time frame: On each experimental session (4hours) the outcome will be measured at the onset on the experiment, which mean prior to the application of the treatment / control and at the end of the experiment which mean 4 hours after the onset.
Dyspnea
Borge modified scale 0 - 10, higher score is a worse outcome
Time frame: On each experimental session (4hours) the outcome will be measured at the onset on the experiment, which mean prior to the application of the treatment / control and at the end of the experiment which mean 4 hours after the onset.
Sleep Quality
Lickert scale 0 - 6, higher score is a better outcome
Time frame: 1 day Follow up
Airway clearance difficulty
Lickert Scale 0 - 6; higher score is a better outcome
Time frame: On each experimental session (4hours) the outcome will be measured at the onset on the experiment, which mean prior to the application of the treatment / control and at the end of the experiment which mean 4 hours after the onset.
Pulsed oxygen saturation
Time frame: Through study completion, 2 days
Cardiac Frequency
Time frame: Through study completion, 2 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain